FDA approves Ventana PD-L1 (SP263) assay for non-small cell lung cancer detection.- Roche
The current standard of care for patients with early stage lung cancer is surgery to remove the tumor, which may be followed by chemotherapy. Unfortunately, about half of these patients will have their cancer return following surgery. Tecentriq received FDA approval on 15 October 2021 as adjuvant treatment following surgery and platinum-based chemotherapy for adults whose Stage II-IIIA NSCLC tumors have PD-L1 expression on at least 1% of tumor cells. The Ventana PD-L1 (SP263) Assay identifies NSCLC patients who may be eligible for Tecentriq (atezolizumab) monotherapy in this indication.
The Ventana PD-L1 (SP263) Assay was used as part of the IMpower010 study sponsored by Genentech/Roche, to identify patients whose tumors expressed the PD-L1 protein. The IMpower010 clinical study began in 2015 with the goal of understanding how patients would respond to treatment with Tecentriq following traditional surgery and chemotherapy. In 2021, Genentech reported a 34% reduction in the risk of disease recurrence or death amongst Tecentriq patients whose tumors were shown to express PD-L1 protein.
Related news and insights
CTI BioPharma Corp. announced the FDA has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109 l.
ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of IMGN 853 (mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).